DRTE Dendrite International (MM)

Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of pharmaceutical industry solutions, today announced the launch of Dendrite MICRO�, a mobile phone enabled sales force effectiveness (SFE) solution designed specifically for life science companies with smaller sales forces. Dendrite MICRO is the first application to be developed on the Company�s recently announced mobile development environment, and provides a convenient, portable and affordable way for emerging life science companies to increase sales force productivity. Dendrite MICRO was specifically designed for life science companies with smaller sales forces, such as medical device companies, and emerging or specialty pharmaceutical companies that require sales force automation technology without the investment of an enterprise solution. The latest offering capitalizes on the robust architecture of Dendrite�s highly scalable flagship SFE platform. Accordingly, companies that begin using Dendrite MICRO as an entry level product have the flexibility to scale the solution to meet changing needs as their sales forces grow. Dendrite MICRO is a mobile phone-based solution that features low up-front investment costs, an easy monthly subscription fee and a preconfigured design for quick deployment without the necessity of complex implementation and training. The solution makes full use of mobile technology with functions like �Near Me,� especially useful for pharmaceutical companies to identify targeted doctors that are closest to the sales representatives, so they can easily fill suddenly cancelled appointments. Dendrite MICRO features the functionality necessary to enable the company to effectively target the right doctor at the right time and with the right message for maximum effectiveness. �Dendrite MICRO is the first of what will be many innovative solutions to be developed on our new mobile development environment announced in August,� said John Bailye, Dendrite�s chairman and chief executive officer. �We are excited about driving mobile innovation into the pharmaceutical and life science market by introducing solutions that will enable both large global enterprises as well as emerging companies tap into the convenience and power of mobile technology.� To learn more about Dendrite MICRO, visit www.dendrite.com/micro. About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company�s clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements. Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of pharmaceutical industry solutions, today announced the launch of Dendrite MICRO(TM), a mobile phone enabled sales force effectiveness (SFE) solution designed specifically for life science companies with smaller sales forces. Dendrite MICRO is the first application to be developed on the Company's recently announced mobile development environment, and provides a convenient, portable and affordable way for emerging life science companies to increase sales force productivity. Dendrite MICRO was specifically designed for life science companies with smaller sales forces, such as medical device companies, and emerging or specialty pharmaceutical companies that require sales force automation technology without the investment of an enterprise solution. The latest offering capitalizes on the robust architecture of Dendrite's highly scalable flagship SFE platform. Accordingly, companies that begin using Dendrite MICRO as an entry level product have the flexibility to scale the solution to meet changing needs as their sales forces grow. Dendrite MICRO is a mobile phone-based solution that features low up-front investment costs, an easy monthly subscription fee and a preconfigured design for quick deployment without the necessity of complex implementation and training. The solution makes full use of mobile technology with functions like "Near Me," especially useful for pharmaceutical companies to identify targeted doctors that are closest to the sales representatives, so they can easily fill suddenly cancelled appointments. Dendrite MICRO features the functionality necessary to enable the company to effectively target the right doctor at the right time and with the right message for maximum effectiveness. "Dendrite MICRO is the first of what will be many innovative solutions to be developed on our new mobile development environment announced in August," said John Bailye, Dendrite's chairman and chief executive officer. "We are excited about driving mobile innovation into the pharmaceutical and life science market by introducing solutions that will enable both large global enterprises as well as emerging companies tap into the convenience and power of mobile technology." To learn more about Dendrite MICRO, visit www.dendrite.com/micro. About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.